Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and Bone Sarcoma Group

@article{Nielsen2000EpirubicinIN,
  title={Epirubicin is not Superior to Doxorubicin in the Treatment of Advanced
Soft Tissue Sarcomas.The Experience of the EORTC Soft Tissue and
Bone Sarcoma Group},
  author={Ole Steen Nielsen and Per Dombernowsky and Henning T. Mouridsen and S\oren Daugaard and M van Glabbeke and Anne Kirkpatrick and Jaap Verweij},
  journal={Sarcoma},
  year={2000},
  volume={4},
  pages={31 - 35}
}
Purpose. Doxorubicin (dox) still appears to be one of the most active drugs in the treatment of soft tissue sarcomas. However, treatment duration is limited due to cumulative cardiotoxicity. A number of small studies from single institutions have suggested activity of other analogues. In two studies the EORTC STBSG tested whether epirubicin (epi) is an alternative to standard dose dox in the treatment of chemonaive patients with advanced soft tissue sarcoma. The present report gives the final… CONTINUE READING
14 Extracted Citations
24 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 14 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 24 references

A randomised phase II trial of caelyx/doxil versus doxorubicin in advanced or metastatic soft tissue sarcomas (STS)Ð An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) trial

  • I Judson, J Radford, J-Y Blay
  • Proc of ASCO 1999;18:541a
  • 1999

The present state of the art in chemotherapy for soft tissue sarcomas in adults : the EORTC point of view

  • J Verweij, HT Mouridsen
  • Crit Rev Oncol / Hematol
  • 1995

A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy

  • GL Plosker, Faulds D. Epirubicin
  • Drugs
  • 1993

Similar Papers

Loading similar papers…